Clal Biotechnology | CBI - Debt


Clal Biotechnology reported ILS35.76M in Debt for its fiscal quarter ending in December of 2023.





Debt Change Date
Arca Biopharma USD 0 0 Mar/2025
aTyr Pharma USD 1.84M 8K Sep/2025
Bio Path USD 261K 261K Mar/2025
Brainstorm Cell Therapeutics USD 1.2M 1.2M Mar/2025
Cara Therapeutics USD 0 0 Mar/2025
Clal Biotechnology ILS 35.76M 28.27M Dec/2023
Compugen USD 2.95M 24K Sep/2025
Immunic USD 0 0 Jun/2024
Infinity Pharmaceuticals USD 0 0 Jun/2022
Minerva Neurosciences USD 0 0 Sep/2024
RedHill Biopharma USD 214K 142K Jun/2025
TherapeuticsMD USD 93.6M 2.82M Sep/2022